Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | FPR2 | P25090 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL680883 | 0.87 | KMT2A (0.42) | HTTKMT2AMEN1TSHRKDM4E | |
| SCHEMBL1259421 | 0.81 | FPR2 (0.42) | KMT2AFPR2MEN1KDM4ELMNA | |
| SCHEMBL680403 | 0.77 | ALDH1A1 (0.45) | KMT2AMEN1KDM4EALDH1A1HSD17B10 | |
| SCHEMBL680891 | 0.75 | LMNA (0.42) | HTTKMT2AMEN1TSHRLMNA | |
| SCHEMBL367875 | 0.72 | FPR2 (0.52) | KMT2AFPR2MEN1TSHRALDH1A1 | |
| SCHEMBL17745549 | 0.70 | NAMPT (0.37) | HTTKMT2ANAMPTMEN1TSHR | |
| SCHEMBL199491 | 0.69 | IGF1R (0.47) | HTTKMT2AMEN1TSHRALDH1A1 | |
| SCHEMBL2676476 | 0.68 | HTT (0.42) | HTTKMT2AMEN1HDAC1HDAC6 | |
| SCHEMBL1258186 | 0.68 | KMT2A (0.46) | KMT2AMEN1KDM4ELMNAALDH1A1 | |
| SCHEMBL14966475 | 0.67 | AXL (0.41) | KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE43878-E1 | Amidophenoxyindazoles useful as inhibitors of c-Met | ELI LILLY AND COMPANY (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2310382-B1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | LILLY CO ELI (US) | 2012-02-22 | — | — | EP | disclosed |
| CN-102105462-A | Amidophenoxyindazoles useful as inhibitors of C-MET | LILLY CO ELI | 2011-06-22 | — | — | CN | disclosed |
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | ELI LILLY AND COMPANY | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022529-A1 | AMIDOPHENOXYINDAZOLES USEFUL AS INHIBITORS OF C-MET | MET, MYCBP, MYC | HTT 4635/4885KMT2A 1681/4885FPR2 1993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.